Abstract
Ischemic brain injury is implicated in the pathophysiology of stroke and brain trauma, which are among the top killers worldwide, and intensive studies have been performed to reduce neural cell death after cerebral ischemia. Alpha 2- adrenergic agonists have been shown to improve the histomorphological and neurological outcome after cerebral ischemic injury when administered during ischemia, and recent studies have provided considerable evidence that alpha 2-adrenergic agonists can protect the brain from ischemia/reperfusion injury. Thus, alpha 2-adrenergic agonists are promising potential drugs in preventing cerebral ischemic injury, but the mechanisms by which alpha 2-adrenergic agonists exert their neuroprotective effect are unclear. Activation of both the alpha 2-adrenergic receptor and imidazoline receptor may be involved. This mini review examines the recent progress in alpha 2-adrenergic agonists - induced neuroprotection and its proposed mechanisms in cerebral ischemic injury.
Keywords: alpha -adrenergic agonist, adrenoceptor, imidazoline receptor, cerebral ischemia, neuroprotection, excitatory amino acids, sympathoinhibition, stroke
Current Neuropharmacology
Title: Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia
Volume: 3 Issue: 4
Author(s): Y. Zhang and H. K. Kimelberg
Affiliation:
Keywords: alpha -adrenergic agonist, adrenoceptor, imidazoline receptor, cerebral ischemia, neuroprotection, excitatory amino acids, sympathoinhibition, stroke
Abstract: Ischemic brain injury is implicated in the pathophysiology of stroke and brain trauma, which are among the top killers worldwide, and intensive studies have been performed to reduce neural cell death after cerebral ischemia. Alpha 2- adrenergic agonists have been shown to improve the histomorphological and neurological outcome after cerebral ischemic injury when administered during ischemia, and recent studies have provided considerable evidence that alpha 2-adrenergic agonists can protect the brain from ischemia/reperfusion injury. Thus, alpha 2-adrenergic agonists are promising potential drugs in preventing cerebral ischemic injury, but the mechanisms by which alpha 2-adrenergic agonists exert their neuroprotective effect are unclear. Activation of both the alpha 2-adrenergic receptor and imidazoline receptor may be involved. This mini review examines the recent progress in alpha 2-adrenergic agonists - induced neuroprotection and its proposed mechanisms in cerebral ischemic injury.
Export Options
About this article
Cite this article as:
Zhang Y. and Kimelberg K. H., Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia, Current Neuropharmacology 2005; 3 (4) . https://dx.doi.org/10.2174/157015905774322534
DOI https://dx.doi.org/10.2174/157015905774322534 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Ventilation During Pediatric CPR
Current Pediatric Reviews Cardiovascular Effects of Ghrelin and Growth Hormone Secretagogues
Cardiovascular & Hematological Disorders-Drug Targets Carbon Monoxide and the Brain: Time to Rethink the Dogma
Current Pharmaceutical Design Magnetic Resonance Spectroscopy Biomarkers in Term Perinatal Asphyxial Encephalopathy: From Neuropathological Correlates to Future Clinical Applications
Current Pediatric Reviews GLP-1, Incretin Mimetics and DPP 4 Inhibitors: New Ways in the Treatment of Type 2 Diabetes
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Importance of Oxidative Damage on the Electron Transport Chain for the Rational Use of Mitochondria-Targeted Antioxidants
Mini-Reviews in Medicinal Chemistry PUFA for Prevention and Treatment of Dementia?
Current Pharmaceutical Design Molecular Mechanisms and Pathophysiology of Necrotic Cell Death
Current Molecular Medicine Antagonists of the Vasopressin V1 Receptor and of the β<sub>1</sub>-Adrenoceptor Inhibit Cytotoxic Brain Edema in Stroke by Effects on Astrocytes-but the Mechanisms Differ
Current Neuropharmacology Long Noncoding RNA OIP5-AS1 Overexpression Promotes Viability and Inhibits High Glucose-Induced Oxidative Stress of Cardiomyocytes by Targeting MicroRNA-34a/SIRT1 Axis in Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Renin Angiotensin System and Cytokines in Chronic Kidney Disease: Clinical and Experimental Evidence
Protein & Peptide Letters Accessing Targeted Nanoparticles to the Brain: The Vascular Route
Current Medicinal Chemistry Coagulation Factor Xa Inhibition: Biological Background and Rationale
Current Topics in Medicinal Chemistry Cross-Talk Between TGF-β and NADPH Oxidases During Liver Fibrosis and Hepatocarcinogenesis
Current Pharmaceutical Design Small Molecule Antagonists of Chemokine Receptors - is Promiscuity a Virtue?
Current Topics in Medicinal Chemistry Recombinant Tissue-Type Plasminogen Activator (Alteplase) in the Management of Acute Ischemic Stroke: A Review of its Pharmacological Properties, Efficacy, Safety and Pharmacoeconomic Aspects
Current Drug Therapy Inhibition of Inflammation by a p38 MAP Kinase Targeted Cell Permeable Peptide
Medicinal Chemistry Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors
Current Pharmaceutical Design Monitoring Cell Therapy Using Iron Oxide MR Contrast Agents
Current Pharmaceutical Biotechnology Targeting Vascular Redox Biology Through Antioxidant Gene Delivery: A Historical View and Current Perspectives
Recent Patents on Cardiovascular Drug Discovery